Instrumento Inactivo

Otros idiomas The Greater Cannabis Company, Inc. Other OTC

Acciones

GCAN

US3916571033

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

The Greater Cannabis Company, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
The Greater Cannabis Company, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy	27/02
The Greater Cannabis Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
GCANRx Featured in American Journal of Endocannabinoid Medicine	21/09/23
The Greater Cannabis Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Nanocap Potential Breakout Watchlist (EPAZ, GCAN, IQST, ONCR)	06/07/23
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders	05/07/23
The Greater Cannabis Company, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
GREATER CANNABIS COMPANY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	13/04/23
The Greater Cannabis Company, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/04/23
The Greater Cannabis Company, Inc. Auditor Raises 'Going Concern' Doubt	13/04/23
Greater Cannabis : Change in Certifying Accountants - Form 8-K	26/01/23
GREATER CANNABIS COMPANY, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	26/01/23
GREATER CANNABIS COMPANY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	14/11/22
The Greater Cannabis Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders	07/10/22
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders	07/10/22
Greater Cannabis Company, Inc. Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders	07/10/22
GREATER CANNABIS COMPANY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	16/08/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas The Greater Cannabis Company, Inc. Other OTC

Acciones

GCAN

US3916571033

Otros idiomas

Filtros